2-乙基-6-异丙基吡嗪 | 32262-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-乙基-6-异丙基吡嗪
• 英文名称: 2-Isopropyl-6-ethylpyrazin
• 英文别名: 2-ethyl-6-isopropyl-pyrazine；2-Ethyl-6-isopropylpyrazine；2-ethyl-6-propan-2-ylpyrazine
• CAS: 32262-93-4
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: XMIMIQPDDJVQAO-UHFFFAOYSA-N

物化性质

• 沸点：
  204.6±35.0 °C(Predicted)
• 密度：
  0.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE N-(5-(6-ÉTHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(MÉTHYLSULFONAMIDO)PYRIMIDIN-4-YL) TÉTRAHYDRO-2H-PYRAN-4-CARBOXAMIDE ET DES COMPOSÉS APPARENTÉS SERVANT D'INHIBITEURS DE CTPS1 HUMAINS POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：STEP PHARMA S A S

  公开号：WO2020245664A1

  公开（公告）日：2020-12-10

  Compounds of formula (I) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6- ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).

  化合物的化学式（I）作为人类胞嘧啶三磷酸合成酶1（CTPS1）抑制剂，用于治疗增殖性疾病，例如癌症，如白血病和淋巴瘤，例如炎症性皮肤病如牛皮癣，或多发性硬化症。本说明书披露了示例化合物的合成和表征，以及其药理学数据（例如，第64至80页；示例；生物学示例1和2；例如，化合物P140，P231至P263；表1至10）。具体示例包括：N-(5-(6-乙氧基吡嗪-2-基)吡啶-2-基)-4-(2-(甲磺酰胺基)嘧啶-4-基)四氢-2H-吡喃-4-羧酰胺（化学式（II）），或1-(2-(环丙磺酰胺基)嘧啶-4-基)-N-(5-(6-乙氧基吡嗪-2-基)吡啶-2-基)环己烷-1-羧酰胺（化学式（III））。
• 4(1H)-QUINOLONE DERIVATIVES AND USES THEREOF
  申请人：Academia Sinica

  公开号：US20200330449A1

  公开（公告）日：2020-10-22

  Compounds of Formula (I) and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents, e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression). Methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding p-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.

  公式(I)的化合物及治疗、延迟和/或预防增生性疾病的不良影响的方法，例如癌症，包括肺癌、乳腺癌、卵巢癌、前列腺癌、头颈癌、头颈癌或白血病（例如，对一种或多种微管靶向药物治疗耐药的癌症，例如对P-糖蛋白（P-gp）过表达相关的多种药物治疗耐药的癌症）。抑制癌细胞微管聚合的方法，适用于需要的个体或细胞、组织或生物样本，结合p-微管蛋白，抑制微管组装，并在组织、生物样本或个体中诱导对多种药物耐药的癌细胞的凋亡。药物组合物、试剂盒和使用上述化合物治疗任何本文描述的靶疾病的方法。
• Siderophore-based immunization against gram-negative bacteria
  申请人：Massachusetts Institute of Technology

  公开号：US10039816B2

  公开（公告）日：2018-08-07

  The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of Formula (I) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium.

  本发明提供了新型肠杆菌素-载体蛋白共轭物和盐霉素-载体蛋白共轭物，如式（I）化合物及其盐。本发明还提供了涉及式（I）化合物的组合物、试剂盒和方法，这些组合物、试剂盒和方法可用于诱导免疫反应、治疗受试者的细菌感染和/或炎症性肠病、预防受试者的细菌感染和/或炎症性肠病，或抑制细菌生长或杀死细菌。
• Uses of salt-inducible kinase (SIK) inhibitors
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10265321B2

  公开（公告）日：2019-04-23

  The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).

  本公开提供了使用盐诱导激酶(SIK)抑制剂，如式(I)的大环SIK抑制剂、式(II)的咪唑基SIK抑制剂和式(III-A)的脲和氨基甲酸酯SIK抑制剂(例如，式(III)的脲和氨基甲酸酯SIK抑制剂)治疗和/或预防炎症性肠病(IBD)和移植物抗宿主病(GVHD)的方法。
• Fused bicyclic pyrimidine derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10342798B2

  公开（公告）日：2019-07-09

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g., PI5P4Kα, PI5P4Kβ, or PI5P4Kγ)) in the subject.

  本发明提供了新颖的式(I)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同分异构体、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及本发明化合物或组合物的方法和试剂盒，用于治疗或预防受试者的增殖性疾病（如癌症（如肺癌、乳腺癌、白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、尤文氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可抑制激酶（如蛋白激酶（如细胞周期蛋白依赖性激酶（CDK）（如 CDK7、CDK12 或 CDK13）或脂质激酶，如磷脂酰肌醇-5-磷酸 4-激酶（PIP4K）（如、PI5P4Kα、PI5P4Kβ 或 PI5P4Kγ））。